RxDoctor Payments Data

Sharon Emmer

Primary Care · Huntington, NYNPI 1649722042

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Merck at 31.0% of the total. Reporting peaked in 2022 at $459 and has fallen 70.6% since, to $135 in 2023.

$737in general payments, 2019–2025

Across 31 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$228
  • Boehringer Ingelheim$171
  • Bayer$167
  • Pfizer$84
  • Johnson & Johnson$70
  • Lilly USA, LLC$17

What the payments were for

  • Food & beverage$737100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck14$228
Boehringer Ingelheim3$171
Bayer3$167
Pfizer5$84
Johnson & Johnson5$70
Lilly USA, LLC1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$737 in reported general payments places this provider in the 60th percentile of 239 primary care providers in New York.

See all primary care providers in New York

Medicare billing

Part B allowed, 2024
$19,394
Medicare patients
139
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levothyroxine Sodium46$680
Metoprolol Succinate41$669
Atorvastatin Calcium63$554
Rosuvastatin Calcium60$528
Albuterol Sulfate HfaAlbuterol Sulfate20$413
Amlodipine Besylate53$346
Azelastine Hcl22$315
Omeprazole36$266
Losartan Potassium36$264
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav26$227
Pantoprazole Sodium23$216
Simvastatin31$193
Propranolol Hcl12$165
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$163
Venlafaxine Hcl ErVenlafaxine Hcl12$153

Paid to pharmacies, not to this prescriber.

Other primary care in Huntington

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →